Comparison of lymphocyte populations, cytokine, and autoantibody profile in patients with rheumatoid arthritis: a study of cases with COVID-19 and controls without COVID-19
DOI:
https://doi.org/10.3855/jidc.21520Keywords:
arthritis, rheumatoid, COVID-19, post-acute COVID-19 syndrome, cytokines, antibodiesAbstract
Introduction: The SARS-CoV-2 pandemic is associated with the development of acute respiratory distress syndrome (ARDS) and post-COVID syndrome (PCS). PSC has been linked to autoimmune diseases, including rheumatoid arthritis (RA), a condition characterized by chronic joint pain driven by dysregulated immune response. This study aims to evaluate the impact of SARS-CoV-2 infection on patients with RA.
Methods: A total of 300 RA patients were included in the study, categorized into two groups: patients with a history of SARS-CoV-2 infection (n = 148) and without prior COVID-19 infection (control group; n = 152). Demographic information, comorbidities, treatments, autoantibodies, cell populations, and cytokines were assessed.
Results: A majority of the patients included in this study were female. A high percentage of patients completed the COVID-19 vaccination schedule. The mean age at RA diagnosis was 44.71 years, with most patients presenting with low disease activity. Patients with a history of SARS-CoV-2 infection reported headache, cough, and fatigue more often. A proportion of these symptoms persisted beyond 12 weeks, consistent with PCS. Autoantibody analysis revealed a high seropositivity rate in both groups, with no statistically significant differences related to SARS-CoV-2 infection. Similarly, the evaluation of immune system cell populations showed no significant variations between groups. Cytokine level analysis also demonstrated no statistically significant differences between cases and controls. However, IL-6 data were unavailable for 37% of participants.
Conclusions: Long-term follow-up did not demonstrate statistically significant alterations in the immunological profile of RA patients with SARS-CoV-2 infection. Nevertheless, further prospective studies are required to elucidate potential long-term immunological effects in this population.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Julian Arias-Aponte, Gabriel E. Acelas-Gonzalez, Rafael Parra-Medina, María Lorcy Monsalve-Córdoba, Adriana Rojas-Villarraga , Paula Daniela Nieto-Zambrano, Hector Fabio Restrepo-Guerrero, Pedro Santos-Moreno, Arley Gómez-López, Maria Camila Cortés-Osma, Laura Villarreal
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
